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Identification of Atropine- and P2X1 Receptor Antagonist-
Resistant, Neurogenic Contractions of the Urinary Bladder
Charles Kennedy, Paul N. Tasker, Gemma Gallacher, and Timothy D. Westfall
Division of Physiology and Pharmacology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 ONR, United
Kingdom
Acetylcholine and ATP are excitatory cotransmitters in parasympathetic nerves. We used P2X1 receptor antagonists to further charac-
terize the purinergic component of neurotransmission in isolated detrusor muscle of guinea pig urinary bladder. In the presence of
atropine (1 M) and prazosin (100 nM), pyridoxalphosphate-6-azophenyl-2,4-disulfonic acid (PPADS) (0.1–100 M) and suramin
(1–300 M) inhibited contractions evoked by 4 Hz nerve stimulation in a concentration-dependent manner (IC50 of 6.9 and 13.4 M,
respectively).Maximum inhibitionwas 50–60%, whichwas unaffected by coadministration of the ectonucleotidase inhibitor ARL67156
(6-N,N-diethyl-D-,-dibromomethyleneATP) (100 M). The remaining responses were abolished by tetrodotoxin (1 M). PPADS and
suramin also reduced contractions to exogenous ATP (300M) by 40–50%, but abolished those to the P2X1 agonist,-methyleneATP
(,-meATP) (1 M). The P2X1 antagonists reactive blue 2, NF279 (8,8-[carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-
phenylenecarbonylimino)] bis-1,3,5-naphthalenetrisulfonic acid), MRS2159 (pyridoxal-5-phosphate-6-phenylazo-4-carboxylic acid)
(100 M), and NF449 [4,4,4 ,4 -(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid] (3
M) abolished contractions to ,-meATP (1 M; n  4–5), but only reduced contractions evoked by 4 Hz nerve stimulation by
40–60% (n 4–6) and ATP by 30–60% (n 4–7). However, prolonged exposure to ,-meATP (50 M) abolished contractions
evoked by all three stimuli (n 5–12). PPADS (100 M) and suramin (300 M) reduced the peak neurogenic contraction of the mouse
urinary bladder to 30–40% of control. At the same concentrations, the P2X1 antagonists abolished the nonadrenergic, purinergic
component of neurogenic contractions in the guinea pig vas deferens (n 4–5). Thus, P2X1 receptor antagonists inhibit, but do not
abolish, thenoncholinergic component of neurogenic contractions of guineapig andmouseurinary bladder, indicating a secondmodeof
action of neuronally released ATP. This has important implications for treatment of dysfunctional urinary bladder, for which this
atropine- and P2X1 antagonist-resistant site represents a novel therapeutic target.
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Introduction
Dysfunction of the urinary bladder is amajor and ever expanding
condition for which highly effective therapeutic options are still
limited (de Groat and Yoshimura, 2001; Andersson and Wein,
2004; Fry et al., 2005). Parasympathetic nerves provide the major
excitatory innervation to the urinary bladder and mediate con-
traction of the detrusor smooth muscle and voiding of urine
(Brading, 1987). The classical neurotransmitter released by these
nerves is acetylcholine (ACh), which acts at postjunctional mus-
carinic receptors, and these are the main target for drugs cur-
rently used to treat dysfunctional bladder. However, as long ago
as the 19th century, a large component of parasympathetic con-
tractions of the urinary bladder was recognized to be resistant to
the muscarinic receptor antagonist atropine in many species
(Langley and Anderson, 1895), and it is now accepted to be me-
diated by a non-adrenergic, noncholinergic (NANC) neuro-
transmitter (Burnstock, 2001). In 1983, Kasakov and Burnstock
showed that the atropine-resistant contractions in the guinea pig
were abolished by desensitization of purinergic P2 receptors by
the ATP analog ,-methyleneATP (,-meATP) and so pro-
posed ATP as the NANC cotransmitter. The inhibitory effect of
,-meATP has since been confirmed in a variety of species, and
the P2X1 receptor, a ligand-gated cation channel, has been iden-
tified as its site of action (Burnstock, 2001; Kennedy, 2001). Thus,
ACh, acting via muscarinic receptors, and ATP, acting through
P2X1 receptors, are widely accepted to be excitatory cotransmit-
ters in the urinary bladder.
In early experiments, desensitization of P2X1 receptors was
used because of the lack of P2X receptor antagonists at that time.
Suramin and pyridoxalphosphate-6-azophenyl-2,4-disul-
phonic acid (PPADS) were the first useful antagonists to appear,
and, although they did inhibit the NANC contractions in the
guinea pig (Hoyle et al., 1990; Creed et al., 1994; Ziganshin et al.,
2002), they were not as effective as ,-meATP. This may reflect
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their low potency at and limited selectivity between P2 receptor
subtypes (Khakh et al., 2001; Lambrecht et al., 2002) or their
ability to inhibit breakdown of ATP by ectonucleotidases (eNTP-
Dases) present on the extracellular surface of smoothmuscle cells
(Hourani and Chown, 1989; Khakh et al., 1995; Ziganshin et al.,
1995; Bu¨ltmann et al., 1999; Lambrecht et al., 2002). In recent
years, more potent and selective P2X1 antagonists have been de-
veloped (Kim et al., 1998, 2001; Lambrecht et al., 2002). There-
fore, the aim of the present study was to characterize the puriner-
gic component of neurogenic contractions of the guinea pig
isolated urinary bladder, using a range of P2X1 receptor
antagonists.
Materials andMethods
Albino male Dunkin Hartley guinea pigs (250–400 g) were killed by
asphyxiation with CO2 and cervical dislocation. The urinary bladder was
removed and cleaned of connective tissue, and four longitudinal strips
(12mm long and 3mmwide) consisting of smoothmuscle andurothe-
lium were prepared as described by Westfall et al. (1997). These were
mounted under isometric conditions in 2 ml horizontal baths and al-
lowed to equilibrate under a resting tension of 1 g at 35°C for 1 h in a
physiological salt solution containing the following (inmM): 118.4 NaCl,
25 NaHCO3, 4.7 KCl, 1.2MgSO4, 1.2 KH2PO4, 2.5 CaCl2, and 11 glucose
(bubbledwith 95%O2, 5%CO2). Atropine (1M) andprazosin (100 nM)
were present throughout. Tensionwas recorded viaDynamometer trans-
ducers (Echometer,Wichita Falls, TX) connected to a Grass Instruments
(Quincy,MA) polygraph or Powerlab/4e system (ADInstruments, Castle
Hill, Australia) using Chart 4.2.4 software (ADInstruments). Intramural
nerves were stimulated by electrical field stimulation (EFS) at 4 Hz for
20 s and supramaximal voltage, via two parallel, platinum wire elec-
trodes, using a Grass Instruments S44 stimulator and Grass Instruments
SIU5F. Initially, a pulse width of 0.5 ms was used, but the contraction
elicitedwas only inhibited by 85.8 1.3% (n 9) by tetrodotoxin (TTX)
(1M), indicating a possible non-neurogenic component to the contrac-
tions. Reducing the pulse width to 0.15 ms elicited contractions, which
were abolished by TTX (1 M), and so in all experiments reported below
this lower pulse width was used. Time-matched controls showed that the
contractions decreased by10% on average over the time course of the
experiments described. At the end of all experiments, TTX (1 M) was
added to confirm that the responses were neurogenic. In one series of
experiments, the urinary bladder of male Olac MF1 mice (4–8 weeks
old) was isolated, mounted, stimulated, and recorded from in the same
manner as described above, except that a single preparationwas obtained
from each animal and the urothelial layer was always removed.
Drugs were added directly to the tissue bathing solution and washed
out by replacement with drug-free solution. Concentration–response
curves for PPADS and suramin against neurogenic contractions were
constructed by obtaining three reproducible control responses to EFS at
10min intervals. A low concentration of antagonist was then added to the
bath, and EFS was reapplied every 10 min until steady-state inhibition
was reached (generally after 30–40 min). Progressively higher concen-
trations of antagonist were then administered in the same manner. The
effects of single concentrations of reactive blue 2, MRS2159 (pyridoxal-
 5-phosphate-6-phenylazo-4-carboxylic acid), NF279 (8,8-[carbonyl-
bis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino)]
bis-1,3,5-naphthalenetrisulfonic acid), and NF449 [4,4,4 ,4 -(car-
bonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-
benzene-1,3-disulfonic acid] on contractions evoked by EFS were
determined in the same way.
Contractions to exogenous agonists were elicited by direct addition to
the bath at 20 min (ACh) and 40 min (,-meATP and ATP) intervals.
Concentration–response curves for PPADS and suramin against ATP
and,-meATPwere constructed as follows. Three reproducible control
agonist responses were obtained. The lowest concentration of antagonist
was then added, and the agonist was reapplied 40 min later. Thereafter,
progressively higher concentrations of antagonist were administered in
the same manner. The effects of single, high concentrations of reactive
blue 2,MRS2159,NF279, andNF449 on contractions evoked byATP and
,-meATP were determined in the same way. The effects of prolonged
administration of ,-meATP were determined as follows. Control re-
sponses to EFS, ATP, and ,-meATP were obtained, and then ,-
meATP (50 M) was applied for 10 min. An additional 50 M ,-
meATPwas added for another 5min. The drugwas thenwashed out, and
EFS, ATP, or ,-meATP was reapplied 5 min later.
Guinea pig vas deferens. In one set of experiments, the vas deferenswere
also removed from the guinea pig, cleaned, andmounted under the same
recording conditions as the urinary bladder. The only difference in the
protocol used was that the sympathetic nerves of the vas deferens were
stimulated by EFS at 4 Hz for 20 s with a pulse width of 0.5 ms. The
contractions evoked were abolished by TTX (1 M).
Statistics. Values in the text refer to mean  SE mean or geometric
mean with 95% confidence limits for IC50 values (after Fleming et al.,
1972). When appropriate, concentration–inhibition response curves for
the antagonists were fitted to the data by logistic (Hill equation), nonlin-
ear regression analysis (Prism; GraphPad, San Diego, CA), and IC50 and
Hill slope (nH) values were calculated. Data were compared by Student’s
paired t test or one-way ANOVA and Tukey’s comparison as appropri-
ate. Differences were considered significant when p 0.05.
Drugs.ATP (disodium salt), ,-meATP (lithium salt), ACh chloride,
atropine sulfate, histamine dihydrochloride, MRS2159 (trisodium salt),
prazosin hydrochloride, and TTX (all from Sigma, Poole, UK),
ARL67156 (6-N,N-diethyl-D-,-dibromomethyleneATP), NF279
(hexasodium salt), NF449 (octasodium salt), reactive blue 2, and PPADS
(tetrasodium salt) (all from Tocris Cookson, Bristol, UK), and suramin
(hexasodium salt) (Bayer, Newbury, UK) were dissolved in distilled
water and stored frozen as 10 or 100 mM stock solutions.
Results
Sensitivity of contractions to P2 receptor antagonists
Stimulation of the parasympathetic nerves of the guinea pig iso-
lated urinary bladder by EFS (4 Hz, 0.15 ms, 20 s) elicited con-
tractions of 3042 148 mg (n 51) that were abolished by TTX
(1M). Atropine (1M) reduced the contraction peak by 27.7
7.9% (n  6), but abolished contractions of similar amplitude
evoked by exogenous ACh (10 M) (3213 157 mg; n 4; data
not shown). Therefore, atropine (1 M) was present throughout
the remainder of the experiments to isolate the noncholinergic
component of parasympathetic neurotransmission.
In the first series of experiments, we constructed concentra-
tion–inhibition curves for PPADS (0.1–100 M) and suramin
(1–300 M) against the atropine-resistant contractions induced
by 4 Hz EFS. Both antagonists inhibited the responses in a
concentration-dependentmanner (Figs. 1, 2, Table 1), but, at the
highest concentrations of antagonists used, the peak contraction
was only depressed by 50–60%. The remaining responses were
abolished by TTX (1 M) (Figs. 1a, 2a), confirming their neuro-
genic origin. To determine whether the antagonist-resistant
component to neurotransmission was specific to 4 Hz stimula-
tion, the effects of antagonists on contractions elicited by EFS at 2
Hz, 0.15ms, 20 s (mean peak amplitude of 2861 282mg; n 7)
were studied. Under these conditions, PPADS (0.1–100 M) and
suramin (1–300M) again inhibited the neurogenic contractions
in a concentration-dependent manner, but by only 40–50%
(Fig. 3).
To confirm that PPADS and suramin fully blocked P2X1 re-
ceptors at the concentrations used, their effects on responses elic-
ited by equi-effective concentrations of the P2X1 agonists ,-
meATP andATPwere investigated.,-meATP (1M) and ATP
(300 M) evoked rapid, transient contractions with peak ampli-
tudes of 3136 162 mg (n 10) and 3365 404 mg (n 12),
respectively. These were inhibited by PPADS (0.1–100 M) and
suramin (1–300 M) in a concentration-dependent manner
(Figs. 1, 2, 4, Table 1). The responses to ,-meATP were abol-
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ished by the antagonists, confirming that PPADS and suramin are
effective antagonists at the P2X1 receptor. However, the peak
response to ATP was reduced by only 40–50%.
The inability of PPADS and suramin to abolish the noncho-
linergic component of neurotransmission and contractions
evoked by exogenous ATP was unexpected. ATP is much less
selective than ,-meATP for P2X1 receptors, and so these data
indicate the presence of an additional contractile P2 receptor that
is activated by ATP, but not ,-meATP and which is insensitive
to PPADS and suramin. Therefore, we next investigated the abil-
ity of other P2 receptor antagonists to inhibit responsesmediated
via the two types of P2 receptor. Initial experiments determined
concentrations of each antagonist that abolished contractions
evoked by ,-meATP (1 M) (n  4–5; data not shown), so
indicating complete blockade of P2X1 receptors. These concen-
trations were then tested against the contractions evoked by 4 Hz
EFS and ATP (300 M). Reactive blue 2 (100 M; n 5), NF279
(100 M; n 6), MRS2159 (100 M; n 5), and NF449 (3 M;
n 4), like PPADS (100M;n 4) and suramin (300M;n 4),
reduced, but did not abolish, the atropine-resistant contractions
evoked by EFS at 4 Hz (Fig. 5a). Suramin ( p  0.001) and
MRS2159 ( p 0.01) were both significantly more effective than
reactive blue 2, NF279, and NF449. The contractions elicited by
ATP (300 M) were also partially resistant to each of the antago-
nists (n 4–7) (Fig. 5b), and reactive blue 2 and MRS2159 were
significantly more effective than NF449 ( p 0.01). In each case,
little reversal of the inhibition was seen on washout of the
antagonists.
Genetic deletion of the P2X1 receptor abolishes noncholin-
ergic, neurogenic contractions in mouse urinary bladder (Vial
and Evans, 2000), so we next investigated the effects of P2X an-
tagonists in mouse tissue to determine whether our data are spe-
cies specific. EFS (4 Hz, 0.15 ms, 20 s) elicited contractions of
mouse detrusor smooth muscle of 465  68 mg (n  8) peak
amplitude. Atropine (1 M) reduced this response by 24.3 
8.8% ( p  0.05; n  3), but abolished contractions evoked by
exogenous ACh (10M) (360 81mg; n 6). In the presence of
Figure 1. The inhibitory effects of PPADS. a, The left trace shows a control, noncholinergic
contraction of a guinea pig isolated urinary bladder muscle strip evoked by EFS (4 Hz, 20 s), the
middle trace shows the response remaining after incubation with PPADS (100M) for 40 min,
and the right trace shows that the contractions were abolished by TTX (1 M). b, The graph
shows themeaneffects of PPADSon the contractions evokedby EFS (4Hz, 20 s;n5) (‚), ATP
(300M; n 6) (Œ), and,-meATP (1M; n 5) (f). Error bars indicate SEM. Atropine (1
M) and prazosin (100 nM) were present throughout.
Figure 2. The inhibitory effects of suramin. a, The left trace shows a control, noncholinergic
contraction of a guinea pig isolated urinary bladder muscle strip evoked by EFS (4 Hz, 20 s), the
middle trace shows the response remaining after incubationwith suramin (300M) for 40min,
and the right trace shows that the contractions were abolished by TTX (1 M). b, The graph
shows the mean effects of suramin on the contractions evoked by EFS (4 Hz, 20 s; n 6) (‚),
ATP (300 M; n 6) (Œ), and ,-meATP (1 M; n 6) (f). Error bars indicate SEM.
Atropine (1M) and prazosin (100 nM) were present throughout.
Table 1. Inhibitory potency of P2 receptor antagonists in the guinea pig isolated
urinary bladder
PPADS Suramin
IC50 (95% cl) (M) nH IC50 (95% cl) (M) nH
4 Hz, 20 s 6.9 (1.3–38.3) 0.57 13.4 (6.6–27.5) 0.75
2 Hz, 20 s 3.7 (1.1–13.1) 0.77 16.2 (5.3– 49.3) 0.77
,-meATP (1M) 5.0 (4.3– 6.0) 1.04 22.5 (14.9–34.1) 1.08
ATP (300M) 6.0 (1.8–19.8) 0.99 15.4 (6.0–39.6) 0.80
Values shownare IC50 and95%confidence limits (95%cl) (inmicromolar) and theHill slopes (nH)obtainedby fitting
the Hill equation to responses obtained in the presence of the antagonists. n 3–8.
Figure 3. The inhibitory effects of PPADS and suramin on contractions of guinea pig isolated
urinary bladder muscle strips evoked by EFS (2 Hz, 20 s). The graph shows the mean SEM of
four experiments with PPADS and three with suramin. Atropine (1M) and prazosin (100 nM)
were present throughout.
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atropine (1 M), PPADS (100 M) and suramin (300 M) re-
duced the peak neurogenic contraction to 28.6  5.0% (n  5)
and 39.5 7.7% (n 6), respectively, of control, values that were
not significantly different from each other. The remaining re-
sponses were abolished by TTX (1M). Therefore, the inability of
combined administration of atropine plus P2X1 receptor antag-
onists to abolish neurogenic contractions of the urinary bladder
is not limited to the guinea pig.
As well as being an excitatory cotransmitter with ACh in para-
sympathetic nerves, ATP is also releasedwith noradrenaline from
sympathetic nerves (Kennedy, 2001), and so we compared the
ability of the P2 receptor antagonists to inhibit sympathetic and
parasympathetic neurotransmission. At the same concentrations
as used above, PPADS, suramin, NF279, MRS2159, and NF449
abolished the prazosin (100 nM)-resistant component of contrac-
tions evoked by 4 Hz EFS in the guinea pig isolated vas deferens
(n  4–5; data not shown) (C. Kennedy, unpublished observa-
tion). Thus, a range of P2 receptor antagonists abolish nonadren-
ergic, sympathetic neurotransmission, but only partially inhibit
noncholinergic, parasympathetic neurotransmission.
The effect of prolonged administration of ,-meATP
The inability of P2X1 receptor antagonists to abolish the
atropine-resistant component of neurogenic contractions is in-
consistent with the reported sensitivity of this response to pro-
longed administration of ,-meATP; therefore, we reinvesti-
gated the effects of ,-meATP. ,-meATP at 50 M evoked a
large, transient contraction of guinea pig detrusor smoothmuscle
(mean peak of 5513 314 mg; n 22) that returned to baseline
over 5–8 min (Fig. 6). Addition of a further 50 M ,-meATP,
10 min after the first, induced a transient contraction that was
22.6 2.2% of the initial response. After a total of 15 min expo-
sure, ,-meATP was washed out, and, 5 min later, responses to
EFS [4 Hz; n 12 (Fig. 6a)], ATP [300 M; n 5 (Fig. 6b)], and
,-meATP [1 M; n  5 (data not shown)] were found to be
abolished. However, contractions evoked by histamine (3 M)
were unaffected (mean peak of 3000  15636 mg before and
2875 736 mg after prolonged ,-meATP; n 4).
Possible mechanisms of resistance to P2X1 blockade
The P2X1 antagonists used above can also inhibit the breakdown
of ATP by ectonucleotidases present on the extracellular surface
of smoothmuscle cells (Khakh et al., 1995; Bu¨ltmann et al., 1999;
Lambrecht et al., 2002). By thus increasing the concentration of
ATP at the synapse, this could counteract their inhibitory effects
and so explain the apparent resistance of the contractions to EFS
and exogenous ATP to P2X1 receptor blockade. To test this hy-
pothesis, the effects of PPADSwere reinvestigated in the presence
of the ectonucleotidase inhibitor ARL67156 (Westfall et al.,
1997). However, PPADS (100M) inhibited contractions evoked
by EFS at 4 Hz to a similar extent in the absence (47.8 3.9% of
control; n 4) and presence (46.8 4.2% of control; n 4) of
ARL67156 (100 M).
Finally, the urothelial layer of the guinea-pig urinary bladder
was present in all of the experiments described above and so
might influence the response to EFS (Maggi, 1993; Fry et al.,
2005). However, there was no significant difference in the inhib-
itory effects of PPADS (100 M) on contractions evoked by 4 Hz
EFS in paired muscle strips from the same animals in which the
urothelium was either present (50.2  4.8% of control) or had
been dissected away (52.2 3.0% of control) (n 5 each).
Figure 4. The inhibitory effects of PPADS (100M) on contractions evoked by,-meATP
(1M) (a) and suramin (300M) on contractions evoked by ATP (300M) (b), in guinea pig
isolated urinary bladdermuscle strips. In both panels, the left trace shows a control contraction,
and the right trace shows the response in the presence of antagonist. Atropine (1 M) and
prazosin (100 nM) were present throughout.
Figure 5. The inhibitory effects of P2 receptor antagonists. a, b, The graphs show themean
effects of PPADS (100M), suramin (300M), reactive blue 2 (100M) (RB2), NF279 (100M),
MRS2159 (100M), and NF449 (3M) on contractions of guinea pig isolated urinary bladder
muscle strips evoked by EFS (4 Hz, 20 s; n 4–6) (a) and ATP (300M; n 4–8) (b). Error
bars indicate SEM. Atropine (1M) and prazosin (100 nM) were present throughout.
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Discussion
These results confirm that ATP acting via P2X1 receptors and
ACh acting through muscarinic receptors are excitatory cotrans-
mitters in the guinea pig and mouse urinary bladder. However,
they also identify a third component of the neurogenic contrac-
tion that is resistant to both atropine and P2X1 antagonists. This
response was not attributable to the following: direct electrical
stimulation of smooth muscle, because TTX abolished all con-
tractions evoked by EFS; neuropeptides released from sensory
nerves, because they play no role in neurogenic contractions in
guinea pig urinary bladder (Maggi, 1993); or adenosine, pro-
duced by breakdown of ATP, because adenosine induces relax-
ation of detrusor smoothmuscle (Brown et al., 1979) and inhibits
contractions elicited by ATP (Lukacsko and Krell, 1982). Con-
tractions evoked by exogenous ATP were also partially resistant
to P2X1 antagonists, but these and all atropine-resistant neuro-
genic contractions were abolished by prolonged exposure to the
P2X receptor agonist ,-meATP. ,-meATP does not induce
heterologous desensitization in the urinary bladder (Kasakov and
Burnstock, 1983), and so these data are consistent with ATP me-
diating the atropine- and P2X1 antagonist-resistant contractions.
The inability of the P2X1 receptor antagonists to abolish con-
tractions evoked by EFS and ATP is unlikely to reflect incomplete
blockade of the P2X1 receptors. The highest antagonist concen-
trations used were up to three orders of magnitude higher than
their IC50 values at P2X1 receptors (Khakh et al., 2001; Kim et al.,
2001; Lambrecht et al., 2002) and abolished contractions of sim-
ilar amplitude evoked by the P2X1 agonist ,-meATP. It is also
unlikely to be attributable to rapid dissociation of the antagonists
from the receptor, so allowing access to ATP, because the antag-
onists showed little reversibility onwashout. The guinea pig P2X1
receptor has yet to be cloned, so it is could have different phar-
macological properties from the human, rat, and mouse P2X1
receptors. However, the agonist potencies of ATP and ,-
meATP at these isoforms are essentially identical (Khakh et al.,
2001; Lambrecht et al., 2002). Antagonist potencies are also very
similar, e.g., NF023 inhibited,-meATP at recombinant rat and
human P2X1 receptors with IC50 values of 0.24 and 0.21 M,
respectively (Soto et al., 1999). In our study, the antagonists also
abolished the P2X1 receptor-mediated, purinergic component of
sympathetic contractions of the guinea pig vas deferens, indicat-
ing that access to the receptors is not restricted. Interestingly,
several analogs of PPADS inhibited neurogenic contractions in
the guinea pig vas deferens, but not the bladder (Kim et al., 1998),
consistent with the differences in antagonist activity in the two
tissues seen here.
The P2X1 antagonist-resistant component is also unlikely to
be attributable to the antagonists inhibiting ATP breakdown by
eNTPDases (Bu¨ltmann et al., 1999; Iqbal et al., 2005), leading to
an increase in the concentration of ATP at the synapse, such that
the inhibition by the P2X1 antagonists was partially reversed
(Kennedy and Leff, 1995). The inhibition of neurogenic contrac-
tions by PPADS was unchanged by the eNTPDase inhibitor
ARL67156, which inhibits ATP breakdown (Westfall et al., 1997).
Additionally, suramin has only a small inhibitory effect on ATP
breakdown in guinea pig detrusor and reactive blue 2 is ineffec-
tive (Hourani and Chown, 1989; Bailey and Hourani, 1994).
Here we constructed full PPADS and suramin concentration–
inhibition curves and showed that the depression of the atropine-
resistant neurogenic contractions reached amaximum of50%.
That the responses were not abolished was initially a surprise,
because neuronally released ATP is accepted to act via P2X1 re-
ceptors to elicit detrusor contraction (Burnstock, 2001; de Groat
and Yoshimura, 2001; Andersson and Wein, 2004; Fry et al.,
2005). However, reexamination of previous studies, in which full
curves were not constructed, shows that they are consistent with
our findings. PPADS at 30M(Ziganshin et al., 2002) and 100M
suramin (Hoyle et al., 1990) inhibited contractions in the guinea
pig evoked at 4 Hz EFS by 30–40%. Similar effects were seen in
rabbit (Ziganshin et al., 1993; Creed et al., 1994), rat (Tong et al.,
1997; Hedge et al., 1998; Benko´ et al., 2003; Knight and Burn-
stock, 2004), and sheep (Creed et al., 1994). The photolysable,
irreversible P2X antagonist ANAPP3 (arylazido aminopropionyl
ATP) also depressed contractions elicited by 4 Hz EFS in guinea
pig by approximately only half (Westfall et al., 1983). Thus, 40–
50% of the peak noncholinergic, neurogenic contraction of the
urinary bladder of a range of species is clearly unaffected by P2X1
receptor antagonists.
Contractions evoked by exogenous ATP were also partly re-
sistant to P2X1 antagonists here, implying that at least two func-
tional P2 receptor subtypes are expressed in guinea pig detrusor
smooth muscle. Consistent with this, the concentration–re-
sponse curve to ATP in this tissue (Welford et al., 1987) (C.
Kennedy, unpublished data) and in humans (Hoyle et al., 1989) is
biphasic. Similar antagonist-insensitive responses toATP are also
seen in the rat (Bolego et al., 1995; Benko´ et al., 2003). In contrast,
the response to ATP was abolished by prolonged exposure to
,-meATP, as reported previously in the guinea pig (Kasakov
Figure 6. a, b, The inhibitory effects of prolonged administration of ,-meATP on con-
tractions of guinea pig isolated urinary bladder muscle strips evoked by EFS (4 Hz, 20 s) (a) and
ATP (300M) (b). The left traces show a control response to EFS or ATP. In the middle, ,-
meATP (50M) was added for 10 min, and then another 50M was added for an additional 5
min. Thedrugwas thenwashedout, and the right traces showthat, 5min later, responses to EFS
andATPwere abolished. Atropine (1M) andprazosin (100 nM)were present throughout. Note
that the response to,-meATP (middle traces) are on a slower timescale than those to EFS
andATP (left and right traces) becauseof theverydifferentdurationsof the responses evokedby
these stimuli.
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and Burnstock, 1983), human (Hoyle et al., 1989), rat (Parija et
al., 1991), and rabbit (Chancellor et al., 1992) (but see Chen et al.,
1992).Why the P2X1 antagonist-resistant component is sensitive
to inhibition by the P2X1 agonist ,-meATP is unclear.
The identity of the P2X1 antagonist-resistant receptor is also
unclear, but all other known P2X receptors, except for the P2X4,
are sensitive to at least one of the antagonists used in this study
(Khakh et al., 2001; Kim et al., 2001; Lambrecht et al., 2002). The
P2X4 homomultimer is probably not involved, because suramin
abolishes the purinergic excitatory junction potentials in the
guinea pig (Hashitani and Suzuki, 1995) and genetic deletion of
the P2X1 subunit abolishes noncholinergic, neurogenic contrac-
tions and responses to exogenous ATP in the mouse (Vial and
Evans, 2000) (although a crucial role of P2X1 subunits in traffick-
ing of P2X4 subunits to the plasma membrane cannot be ruled
out). A role for a P2X1  4 heteromultimer can, however, be
considered. Rat P2X1 and P2X4 subunits coinjected into Xenopus
oocytes copurify and form a novel functional phenotype, at
which ,-meATP is a weak partial agonist (Nicke et al., 2005).
This could explain the ability of ,-meATP to inhibit the P2X1
antagonist-insensitive component of contractions to EFS and
ATP in the urinary bladder. However, the sensitivity of the
P2X1  4 heteromer to suramin was much greater than that of
the P2X4 homomer, although a full concentration–inhibition
curve was not constructed. Clearly, more studies are required to
determine the involvement of P2X4 subunits in parasympathetic
neurotransmission.
It is unlikely that P2Y receptors mediate the P2X antagonist-
resistant responses seen in the present study, although P2Y recep-
tor agonists induce contraction of guinea pig (Bailey and Hou-
rani, 1994) and rat (Bolego et al., 1995; Naramatsu et al., 1997)
bladder. Of the eight cloned P2Y receptors, ATP is an agonist at
the P2Y1, P2Y2, P2Y4, and P2Y11 subtypes, but suramin and/or
PPADS antagonize each of these (Abbracchio et al., 2006). Con-
sistentwith this, suramin abolished contractions in the guinea pig
evoked by the P2Y agonists cytidine 5-triphosphate, inosine 5-
triphosphate, and uridine 5-triphosphate (UTP) but only par-
tially inhibited those to ATP (Bailey and Hourani, 1994). Addi-
tionally, UTP-evoked contractions of rat detrusor were
unaffected by prolonged exposure to ,-meATP (Bolego et al.,
1995). Additional experiments on guinea pig recombinant P2Y
receptors, once cloned, are needed to confirm this conclusion.
In contrast to non-primates, ACh is the sole excitatory neuro-
transmitter in the healthy human urinary bladder (Fry et al.,
2005), sowhat is the relevance of the present data to humans? The
potential importance is attributable to the appearance of
atropine-resistant contractions in unhealthy human bladder
conditions, such as interstitial cystitis and idiopathic detrusor
instability (IDI) (Fry et al., 2005). These contractions are abol-
ished by prolonged exposure to ,-meATP and so assumed to
be mediated by ATP and P2X1 receptors, but this has not been
confirmed using P2X1 receptor antagonists. Furthermore, al-
though the P2X1 is the main P2X subunit present in human de-
trusor smooth muscle, its expression is unchanged in dysfunc-
tional bladder (Moore et al., 2001; O’Reilly et al., 2002). It is
notable that the P2X4 subunit is also expressed, and its colocal-
ization with nerve varicosities more than doubles in tissue from
adults with IDI (Moore et al., 2001; O’Reilly et al., 2002). Inter-
estingly, pregnancy in rats is also associated with an increase in
P2X4 subunit junctional clustering (Yunaev et al., 2000), and the
PPADS-sensitive component of neurogenic contractions is
smaller in pregnant rats (Knight and Burnstock, 2004).
Other proposed explanations for the appearance of a puriner-
gic component of parasympathetic neurotransmission in human
urinary bladder include that more ATP is released from motor
nerves and that ATP is broken down less effectively in the synapse
(Fry et al., 2005). To these must be added the possibility that the
purinergic component is not mediated by the P2X1 receptor
alone, and the novel component postulated here plays a role. This
has important implications for the search for new drugs to treat
dysfunctional bladder because it identifies a new therapeutic tar-
get for what is a major and expanding therapeutic problem. Fur-
thermore, a receptor that is only functional in dysfunctional uri-
nary bladder is an attractive target for drug development.
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